Rep. Ronny Jackson

Maddy summaryHR 683 (PASS Act of 2023) expands the Committee on Foreign Investment in the United States (CFIUS) review process to cover foreign investments in U.S. agriculture businesses, agricultural biotechnology, and private farmland. It mandates that the President block transactions involving foreign entities from China, Russia, Iran, or North Korea that would give them control over U.S. agricultural operations or land used for farming. The bill allows limited presidential waivers for national security reasons but requires a 30-day review period before any waiver. Additionally, it requires the Secretary of Agriculture to submit biannual reports to Congress on risks posed by foreign ownership in U.S. agriculture.

Maddy summaryThis symbolic House resolution (HRES 72) recognizes independent workers, contractors, and freelancers for their economic contributions to the U.S. It highlights their role in the growing flexible work economy and acknowledges the benefits of flexible work arrangements, such as freedom in hours and locations. The resolution does not create new laws or alter existing policies - it solely serves as a formal acknowledgment of these workers' significance to the economy. It references their $1.35 trillion economic contribution in 2022 and their growing share of the workforce (39% of U.S. workers).

This resolution expresses support for the Supreme Court's holding in Dobbs v. Jackson Women's Health Organization (that there is no constitutional right to abortion). The resolution also applauds the courage of the Justices for standing by their allegiance to the Constitution and the legitimacy of the Supreme Court, and it expresses a commitment to supporting policies that continue to protect all life.

This resolution expresses the sense of the House of Representatives that (1) the President should classify synthetic illicit fentanyl-related substances as weapons of mass destruction; and (2) illicit fentanyl, and illicit fentanyl-related substances, should be permanently placed in schedule I (i.e., as drugs, substances, or chemicals with no currently accepted medical use and a high potential for abuse).

Maddy summaryThe HEAL Act (HR 603) requires the U.S. Holocaust Memorial Museum Director to study how public elementary and secondary schools teach about the Holocaust and related antisemitism. The study will examine curriculum requirements, teaching methods (like project-based learning), instructional materials, and assessment approaches across states and school districts. It specifically analyzes whether Holocaust education is mandatory, optional, or integrated across subjects, and how schools address antisemitism and genocide prevention. The resulting report, due within 180 days of the study or three years after enactment, will inform Congress but does not change current school policies. This is a data-gathering measure, not a policy mandate.

Prohibiting Abortion Industry's Lucrative Loopholes Act This bill expands the prohibition on the sale or purchase of human fetal tissue in interstate commerce to include any payments associated with the transportation, implantation, processing, preservation, quality control, or storage of such tissue.

Protecting Life and Integrity in Research Act of 2023 This bill restricts research that uses human fetal tissue from an induced abortion. Specifically, it prohibits the Department of Health and Human Services from conducting or supporting such research. Additionally, the bill applies requirements on the research of transplantation of fetal tissue for therapeutic purposes to research on fetal tissue in general. The bill also prohibits soliciting or acquiring a donation of human fetal tissue from an induced abortion, other than for purposes of an autopsy or burial.

Maddy summaryThis bill would prohibit the FDA from approving new abortion medications or investigational uses of existing ones. It would restrict currently approved abortion drugs to in-person administration only in clinics, hospitals, or medical offices by certified providers who can handle complications like ectopic pregnancy or severe bleeding. The law requires detailed adverse event reporting (excluding patient identifiers) to the FDA by both manufacturers and prescribers, and mandates provider certification covering pregnancy assessment, surgical intervention capabilities, and patient safety documentation. These provisions apply directly to healthcare providers, patients seeking medication abortions, and manufacturers of abortion drugs.

Protecting Life and Taxpayers Act of 2023 This bill requires federally funded entities to certify that they will not, subject to certain exceptions, perform abortions or provide funding to other entities that perform abortions. The bill provides exceptions for abortions (1) in cases of rape or incest; or (2) when the life of the woman is in danger due to a physical disorder, injury, or illness.

This bill nullifies certain changes made by the Food and Drug Administration (FDA) to dispensing requirements for mifepristone. (Mifepristone is a drug that is approved to end pregnancies through 10 weeks gestation when used in conjunction with the drug misoprostol. The procedure is often referred to as medication abortion or the abortion pill.) The FDA regulates the use of mifepristone through the Mifepristone Risk Evaluation and Mitigation Strategy (REMS) program. The program requires health care providers to comply with certain requirements in order to prescribe or dispense mifepristone to end a pregnancy; the program previously included an in-person dispensing requirement that required mifepristone to be directly dispensed to patients in clinics, medical offices, or hospitals. During the COVID-19 public health emergency, the FDA temporarily stopped enforcing the in-person dispensing requirement, which allowed mail-order pharmacies to fill and dispense mifepristone prescriptions. In January 2023, the FDA modified program requirements so as to (1) remove the in-person dispensing requirement, and (2) require pharmacies to be certified in the program in order to dispense mifepristone. The modifications allow retail pharmacies, after receiving certification, to dispense mifepristone pursuant to prescriptions that are written by program-certified prescribers. The bill nullifies the January 2023 changes and prohibits any similar changes in the future.